未知股票 VIRX 深 滬
已收盤
--
0.000
NaN.00%
華盛通- 最 高--
- 今 開--
- 成交量 --
- 最 低 --
- 昨 收 --
- 總市值 0
- 52周最高 --
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 總股本 3974.42万
- 歷史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 歷史最低 --
- 每 手 1
- 風險率 0.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Viracta falls on plans to explore strategic options
Cancer drug developer Viracta Therapeutics (NASDAQ:VIRX) traded ~15% lower in the premarket on Friday after announcing plans to explore strategic alternatives, including a sale or a merger deal, to ma...
2024-12-27 22:04
US Stocks To Open Lower As Index Future Decline: Analysts Remain Upbeat About Santa Rally
U.S. stock futures tumbled on Friday in premarket hours after a mixed Thursday. All four index futures slipped in trade.
2024-12-27 20:35
Viracta Therapeutics Explores Strategic Options After NAVAL-1 Closure
Viracta Therapeutics ( ($VIRX) ) just unveiled an update. Viracta Therapeutics ...
2024-12-27 05:57
快讯 | Viracta Therapeutics：现金状况足以支撑运营直到2025年第一季度末
Viracta Therapeutics: Cash Position Sufficient to Fund Operations Late Into Q1 ...
2024-11-13 20:02
快讯 | Viracta Therapeutics第三季度净利润为-1060万美元
Viracta Therapeutics Q3 Net Income USD -10.6 Million
2024-11-13 20:00
快讯 | Viracta Therapeutics宣布重新调配资源，以加强对复发性或难治性EBV阳性外周T细胞淋巴瘤患者的Nana-Val开发计划的关注
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus o...
2024-11-07 05:30
快讯 | Viracta Therapeutics Inc：Leerink合作伙伴将目标价从5美元下调至3美元，将其评级从跑赢大盘降至市场表现。
Viracta Therapeutics Inc : Leerink Partners Cuts to Market Perform From Outperf...
2024-08-16 13:51
RBC Capital Maintains Outperform on Viracta Therapeutics, Lowers Price Target to $4
RBC Capital analyst Gregory Renza maintains Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and lowers the price target from $6 to $4.
2024-08-15 22:55
快讯 | Viracta Therapeutics公司：瑞银将目标价从6美元下调至4美元
Viracta Therapeutics Inc : RBC Cuts Target Price to $4 From $6
2024-08-15 14:11
Why Is Cancer-Focused Penny Stock Viracta Therapeutics Trading Higher On Wednesday?
Viracta Therapeutics stock gains after Phase 2 NAVAL-1 trial results for relapsed or refractory EBV+ PTCL cohort. The company plans pipeline reprioritization and a reduction in force.
2024-08-14 21:19
